Regeneron slump continues as analysts turn more cautious
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)
September 26, 2024 5:56 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $1,247.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Today the Federal Circuit issued an order to temporarily enjoin Amgen from launching its Eylea biosimilar until further notice. As a... More
Truist Securities Reiterates Buy Rating on Amgen (AMGN)
September 25, 2024 5:43 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Earlier this evening, Amgen (AMGN, Buy) provided positive Ph3 updates from two key pipeline programs - Uplizna in gMG and rocatinlimab in atopic... More
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
September 24, 2024 2:18 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
